{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:19:05Z","timestamp":1793992745003,"version":"4.8.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>ROS1 tyrosine kinase inhibitors are one of the primary immunotherapies for ROS1 fusion-positive cancers. Tyrosine kinase inhibitors have markedly improved outcomes for advanced cancers previously with poor prognosis. Entrectinib is an example of an ROS1 inhibitor that can be used for lung adenocarcinoma. There are numerous adverse effects with rare cardiac side effects reported, such as heart failure and myocarditis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>A 27-year-old male being treated for lung adenocarcinoma who presented new congestive heart failure 2 weeks after starting Entrectinib. He developed refractory ventricular tachycardia, cardiogenic shock with an endomyocardial biopsy that showed active lymphohistiocytic myocarditis. With antiarrhythmic therapy, heavy sedation, mechanical circulatory support, and high-dose steroids, the patient had complete resolution of symptoms and return to baseline status.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>This is a rare case with a severe complication after starting Entrectinib for lung adenocarcinoma. In the literature, this is the first case of its kind presenting with myocarditis and severe heart failure after treatment with Entrectinib. This case highlights not only using cardiac imaging, and biopsy to help guide the diagnosis, but also describe the appropriate management.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytae650","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:49:54Z","timestamp":1733878194000},"source":"Crossref","is-referenced-by-count":8,"title":["Case report of entrectinib associated fulminant myocarditis"],"prefix":"10.1093","volume":"9","author":[{"given":"Gohar","family":"Rundhawa","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, York Hospital, WellSpan Health , 30 Monument Rd, York, PA 17403 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3099-5299","authenticated-orcid":false,"given":"Murtaza","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, York Hospital, WellSpan Health , 30 Monument Rd, York, PA 17403 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Jacob","sequence":"additional","affiliation":[{"name":"Department of Cardiology, York Hospital, WellSpan Health , 30 Monument Rd, York, PA 17403 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond","family":"Obeng-Gyimah","sequence":"additional","affiliation":[{"name":"Department of Cardiology, York Hospital, WellSpan Health , 30 Monument Rd, York, PA 17403 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N","family":"Vranian","sequence":"additional","affiliation":[{"name":"Department of Cardiology, York Hospital, WellSpan Health , 30 Monument Rd, York, PA 17403 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"2025012113091853700_ytae650-B1","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"2025012113091853700_ytae650-B2","first-page":"e32174","article-title":"Entrectinib-induced heart failure in a patient with metastatic lung adenocarcinoma: a case report","volume":"14","author":"Otsu","year":"2022","journal-title":"Cureus"},{"key":"2025012113091853700_ytae650-B3","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/j.jacc.2021.04.009","article-title":"Clinical approach to cardiovascular toxicity of oral antineoplastic agents: JACC state-of-the-art review","volume":"77","author":"Rao","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2025012113091853700_ytae650-B4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"key":"2025012113091853700_ytae650-B5","author":"FDA"},{"key":"2025012113091853700_ytae650-B6","article-title":"Monitoring and treatment of cardiovascular complications during cancer therapies","author":"Poku"},{"key":"2025012113091853700_ytae650-B7","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC Scientific Document Group, 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-oncology Society (IC-OS): developed by the Task Force on cardio-oncology of the European Society of Cardiology (ESC)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2025012113091853700_ytae650-B8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11886-022-01680-x","article-title":"State-of-the-art of endomyocardial biopsy on acute myocarditis and chronic inflammatory cardiomyopathy","volume":"24","author":"Ammirati","year":"2022","journal-title":"Curr Cardiol Rep"},{"key":"2025012113091853700_ytae650-B9","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","article-title":"International Consensus Group on cardiovascular magnetic resonance in myocarditis. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper","volume":"53","author":"Friedrich","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2025012113091853700_ytae650-B10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/bcr-2021-243946","article-title":"Entrectinib-related myocarditis in a young female patient with metastatic non-small cell lung cancer","volume":"14","author":"Fonseca","year":"2021","journal-title":"BMJ Case Rep"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytae650\/61008756\/ytae650.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/9\/1\/ytae650\/61008756\/ytae650.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/9\/1\/ytae650\/61008756\/ytae650.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T13:10:00Z","timestamp":1737465000000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytae650\/7919780"}},"subtitle":[],"editor":[{"given":"Clement","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Duygu Kocyigit","family":"Burunkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Andreas","family":"Metzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Kemal Emrecan","family":"Parsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Reshma","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Deepti","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytae650","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,12,10]]},"article-number":"ytae650"}}